March 01, 2026

#safety — Sunday, March 01, 2026 (2 items)

hot top new

0		💬 0	Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial. (linkinghub.elsevier.com)	Anywaine Z … Kaleebu P Lancet Infectious Diseases 2026-03-01	#vaccination #clinical trial #immunogenicity #safety #zoonosis
0		💬 0	Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com)	Wagner L … Messier M Lancet Infectious Diseases 2026-03-01	#vaccination #clinical trial #immunogenicity #safety #lyme borreliosis